Cargando…

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice

INTRODUCTION: Real-world trial data comparing single- with multiple-inhaler triple therapy (MITT) in COPD patients are currently lacking. The effectiveness of once-daily single-inhaler fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) and MITT were compared in usual clinical care. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halpin, David M.G., Worsley, Sally, Ismaila, Afisi S., Beeh, Kai-Michael, Midwinter, Dawn, Kocks, Janwillem W.H., Irving, Elaine, Marin, Jose M., Martin, Neil, Tabberer, Maggie, Snowise, Neil G., Compton, Chris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181617/ https://www.ncbi.nlm.nih.gov/pubmed/34109236 http://dx.doi.org/10.1183/23120541.00950-2020

Ejemplares similares

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
por: Worsley, Sally, et al.
Publicado: (2019)

Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
por: Halpin, David M G, et al.
Publicado: (2022)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting
por: Halpin, David M G, et al.
Publicado: (2022)

Matching the Inhaler to the Patient in COPD
por: Peché, Rudi, et al.
Publicado: (2021)

Trepid and Intrepid Travelers
por: Granowitz, Eric V.
Publicado: (2005)

Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England
por: Rothnie, Kieran J, et al.
Publicado: (2022)

Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
por: Kendall, Robyn, et al.
Publicado: (2023)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review
por: Zhang, Shiyuan, et al.
Publicado: (2020)

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
por: Ismaila, Afisi S., et al.
Publicado: (2023)

Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial
por: Ismaila, Afisi S., et al.
Publicado: (2017)

COPD management: role of symptom assessment in routine clinical practice
por: van der Molen, Thys, et al.
Publicado: (2013)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
por: Bourbeau, Jean, et al.
Publicado: (2021)

The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide?
por: van der Molen, Thys, et al.
Publicado: (2014)

A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
por: Ismaila, Afisi S., et al.
Publicado: (2023)

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
por: Fenwick, Elisabeth, et al.
Publicado: (2021)

Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands
por: van Boven, Job FM, et al.
Publicado: (2016)

Towards Rational Prescription of Common Inhaler Medication in the Multimorbid COPD Patient
por: Tsiligianni, Ioanna, et al.
Publicado: (2021)

The use of Biofeedback in Clinical Virtual Reality: The INTREPID Project
por: Repetto, Claudia, et al.
Publicado: (2009)

FreeBSD device drivers: a guide for the intrepid
por: Kong, Joseph
Publicado: (2012)

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
por: Martin, Alan, et al.
Publicado: (2022)

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
por: Gabrio, Andrea, et al.
Publicado: (2022)

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
por: Requena, Gema, et al.
Publicado: (2023)

Patient public involvement and engagement in thrombosis research: Not just for the intrepid
por: Højen, Anette Arbjerg, et al.
Publicado: (2020)

Transapical implantation of the Intrepid device: Case planning and operative technique
por: Hong, Estee, et al.
Publicado: (2020)

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review
por: Dyer, Matthew J, et al.
Publicado: (2006)

Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2022)

Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England
por: Sansbury, Leah B, et al.
Publicado: (2021)

A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD
por: Ming, Simon Wan Yau, et al.
Publicado: (2020)

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England
por: Requena, Gema, et al.
Publicado: (2022)

Memorials to John Snow – Pioneer in anaesthesia and epidemiology
por: Snowise, Neil G
Publicado: (2021)

INTREPID—INformation-theoretic TREe traversal for Protein functional site IDentification
por: Sankararaman, Sriram, et al.
Publicado: (2008)

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
por: Tabberer, Maggie, et al.
Publicado: (2020)

Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ)
por: Tsiligianni, Ioanna G, et al.
Publicado: (2012)

Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England
por: Sansbury, Leah B, et al.
Publicado: (2021)

Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials
por: Riley, John H, et al.
Publicado: (2016)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
por: Bremner, Peter R., et al.
Publicado: (2018)

INTREPID: a web server for prediction of functionally important residues by evolutionary analysis
por: Sankararaman, Sriram, et al.
Publicado: (2009)

Concepts of madness in diverse settings: a qualitative study from the INTREPID project
por: Cohen, Alex, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kdm8e7a8lucambhib6lqs1q1sl